J&J submits Risperdal follow-on
Executive Summary
Johnson & Johnson submits NDA for paliperidone extended-release Nov. 29, giving the schizophrenia therapy a user fee date in late September 2006. The timeline puts J&J on track to launch paliperidone ER in advance of generic competition to Risperdal (risperidone), which could lose exclusivity as early as mid-2008. The agent is a metabolite of risperidone and uses J&J's proprietary OROS controlled-release technology, gained through the company's acquisition of Alza in 1999 (1"The Pink Sheet" April 19, 2004, p. 12)...
You may also be interested in...
J&J Antipsychotic Paliperidone ER Moves Into Phase III
Johnson & Johnson has moved a potential successor compound to the antipsychotic Risperdal into Phase III clinical studies
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.